Black Fungus: An Alarming Infection During Novel Coronavirus: A Review

Mucormycosis is the most emerging angioinvasive fungal infection of filamentous fungi of the Zygomycetes class, which, when neglected, causes severe disseminated infection along with significant chances of morbidity and mortality. The diagnosis and treatment remain challenging for the doctors. It has been observed that people who have been suffering from different diseases, such as hematological malignancies and uncontrolled diabetes, or who have gone through different surgeries, such as hematopoietic stem cell transplant, and solid transplantation, are the most affected ones. On the other hand, people who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically show the symptoms of mucormycosis after 1-2 weeks of successful recovery. Standard treatment of mucormycosis is traditionally considered an amphotericin B intravenous (IV) drug as initial therapy, although posaconazole and isavuconazole are also used. The core objective of the review is to typically focus on the area of the sudden cause of mucormycosis in the patients who have already recovered from SARS-CoV-2.